Mario Mandala
Expertise in
3
conditions

Mario Mandala

Perugia, IT 
Expertise in
3
conditions
Perugia, IT 

Overview

Mario Mandala practices practicing medicine in Perugia, Italy.

Mr. Mandala is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Melanoma, Venous Thromboembolism (VTE), Metastatic Brain Tumor, and Gastroesophageal Junction Cancer.

He is actively involved in clinical research, co-authoring 251 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Perugia, Italy
Other Locations
Siena, 53100, Italy
Rende, Italy
Bergamo, Italy
Santa Maria, Italy
Azienda Ospedaliero Careggi, Toscana
Florence, Italy
Verona, Italy
Treviglio, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Nivolumab + Ipilimumab, Encorafenib + Binimetinib
Study Phase: Phase 2
A Phase II, Single Arm Study Investigating Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in High Risk, Surgically Resectable, Stage III Cutaneaous Squamous Cell Carcinoma
A Phase II, Single Arm Study Investigating Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in High Risk, Surgically Resectable, Stage III Cutaneaous Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Cemiplimab
Study Phase: Phase 2
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
Enrollment Status: Completed
Publish Date: June 07, 2024
Intervention Type: Drug
Study Drugs: LGX818, MEK162, Nivolumab, Ipilimumab
Study Phase: Phase 2
Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study
Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study
Enrollment Status: Active_not_recruiting
Publish Date: January 05, 2024
Intervention Type: Drug, Other
Study Drug: Nivolumab+Ipilimumab
Study Phase: Phase 2
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
Enrollment Status: Unknown
Publish Date: September 28, 2023
Intervention Type: Drug
Study Drugs: CAPOX, Capecitabine, FOLFIRI
Study Phase: Phase 2
View 4 Less Clinical Trials

251 Total Publications

Hemostatic Aspects of Interactions Between Anticancer Drugs and Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism.
Hemostatic Aspects of Interactions Between Anticancer Drugs and Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism.
Journal: Seminars in thrombosis and hemostasis
Published: May 12, 2026

Frequently Asked Questions about Mario Mandala

Is Mario Mandala a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Mario Mandala is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mario Mandala participate in research or clinical trials?

Yes. Mario Mandala has published 251 articles and abstracts on conditions like Melanoma. You can view a list of Mario Mandala's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mandala's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile